School of Medicine
Showing 1-20 of 160 Results
-
Ranjana Advani
Saul A. Rosenberg, MD, Professor of Lymphoma
Current Research and Scholarly InterestsClinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.
The research program is highly collaborative with radiation oncology, industry, pathology and dermatology. -
Ash A. Alizadeh, MD/PhD
Moghadam Family Professor
Current Research and Scholarly InterestsMy research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.
Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials. -
Danielle Francoise Atibalentja, MD, PhD
Instructor, Medicine - Oncology
BioDanielle F Atibalentja received her PhD in Immunology at Washington University in St Louis and her MD at UCSF School of medicine. She trained in Internal medicine at Washington University/Barnes-Jewish Hospital in St Louis and recently completed Hematology/Oncology Fellowship at Stanford. Her primary clinical interest is in treating patients with B-cell lymphomas. Her long-term research goals are to better understand B-cell responses in the setting of malignancy to develop immune-based therapies for cancer treatment. She currently studies how the MYC oncogene shapes B-cell and antibody responses during T-cell lymphomagenesis.
-
Xiangqi Bai
Postdoctoral Scholar, Oncology
BioMy research is focused on computational and systems biology. My primary research interest lies in developing new computational algorithms and statistical methods for the analysis of complex data in biological systems, especially related to the large-scale single-cell RNA sequencing data. The specific topics I have examined include:
1. Integration of single-cell multi-omics datasets for tumor
2. Statistical test of cell developmental trajectories
3. Visualization and reconstruction of single-cell RNA sequencing data
4. Computational analysis of the bifurcating event revealed by dynamical network biomarker methods -
Allison Betof, MD, PhD
Associate Professor of Medicine (Oncology)
BioDr. Allison Betof is an Associate Professor of Medicine (Oncology), Director of the Melanoma Program, Director of Solid Tumor Cellular Therapy, and Mark & Mary Stevens Endowed Scholar in Melanoma at Stanford University School of Medicine. Dr. Betof completed her MD and PhD at Duke University, Internal Medicine residency at Massachusetts General Hospital (Harvard University) and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Betof’s laboratory focuses on understanding resistance to immune checkpoint blockade and cellular therapies for melanoma and other solid tumors. She is the Principal Investigator of clinical trials exploring novel treatments for immunotherapy-refractory melanoma and is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. Dr. Betof has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy for the treatment of melanoma and other solid tumors. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), Melanoma Research Alliance, and Melanoma Research Foundation.
-
Douglas W. Blayney
Professor of Medicine (Oncology), Emeritus
Current Research and Scholarly InterestsImproving the quality of cancer care at Stanford, in our network of care, and nationally
-
Nam Quoc Bui
Clinical Associate Professor, Medicine - Oncology
BioDr. Bui is a Clinical Associate Professor of Medicine at the Stanford Cancer Institute and a specialist in Sarcoma. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data.
He is involved in numerous sarcoma clinical trials, leading efforts to take new therapeutics from the lab to clinical practice. His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies. He also is involved in education at the Stanford University School of Medicine, serving as a lecturer and mentor to medical students, residents, and oncology fellows. Dr. Bui is the founding Editor-in-Chief of the journal “Current Problems in Cancer: Case Reports”, an international, peer-reviewed journal that publishes groundbreaking cases that give insight into redefining concepts in cancer. He also serves as the Chair of the Data Safety Monitoring Committee at the Stanford Cancer Institute, overseeing the board that reviews all investigator-initiated cancer trials run at Stanford. -
Robert W. Carlson
Professor of Medicine (Oncology and General Internal Medicine/Medical Informatics) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsClinical investigations in breast cancer include institutional and NSABP studies of chemoprevention, adjuvant therapy, psychosocial interventions, treatment of metastatic disease, methods of decreasing anthracycline cardiotoxicity, and modulation of multidrug resistance. Research in meta-analysis includes the performance of meta-analysis in a wide variety of settings in cancer treatment by the international Meta-Analysis Group in Cancer.
-
Jennifer Caswell-Jin
Assistant Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMy research is on the translational application of next-generation sequencing technologies to breast cancer care: (1) the value of hereditary cancer genetic panel testing in clinical practice, (2) the mechanisms by which inherited genetic variants lead to breast cancer development, and (3) the analysis of somatic tumor sequencing data to inform understanding of breast tumorigenesis, metastasis, and development of resistance in response to therapeutics.
